As naloxegol nears end zone, Nektar seeks $108.4M for pipeline

By Marie PowersStaff Writer

Thursday, January 23, 2014

After pocketing a $70 million milestone payment from partner Astrazeneca plc in November following the FDA’s acceptance of the new drug application (NDA) for lead compound naloxegol, Nektar Therapeutics Inc. turned to the public markets in a big way to advance its internal programs.